Park Jungeun, Kim Sangmi, Oh Jong K, Kim Jin Y, Yoon Sung Soo, Lee Dongsoon, Kim Youngsoo
Division of Molecular Genomic Medicine and #Cancer Research Institute, College of Medicine, Seoul National University, Yongon-Dong, Seoul 110-799, Korea.
J Biochem Mol Biol. 2005 Nov 30;38(6):725-38. doi: 10.5483/bmbrep.2005.38.6.725.
Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein expression profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in the presence and absence of imatinib mesylate. We identified 118 differentially regulated proteins in these two leukemia cell-lines, with and without a 1 microM imatinib mesylate challenge. Nine proteins of unknown function were discovered. This is the first comprehensive report regarding differential protein expression in imatinib mesylate-treated CML cells.
对甲磺酸伊马替尼（也称为格列卫、格列维克和STI571）产生耐药性常常成为慢性粒细胞白血病（CML）治疗的障碍。为了确定甲磺酸伊马替尼的作用标志物，我们采用质谱分析法比较了在有和没有甲磺酸伊马替尼存在的情况下，人白血病细胞（K562）和耐甲磺酸伊马替尼的人白血病细胞（K562-R）中的蛋白质表达谱。在有和没有1 microM甲磺酸伊马替尼刺激的情况下，我们在这两种白血病细胞系中鉴定出118种差异调节蛋白。发现了9种功能未知的蛋白质。这是关于甲磺酸伊马替尼治疗的CML细胞中差异蛋白质表达的第一份全面报告。
